Literature DB >> 23725618

Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis.

Williamson Z Bradford, Alan H Cohen, Jonathan A Leff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23725618     DOI： 10.1164/rccm.201204-0770LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  5 in total

1.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

2.  Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Williamson Z Bradford; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; David Kardatzke; Talmadge E King; Lisa H Lancaster; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Jeffrey J Swigris; Paul W Noble
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

3.  Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Authors:  Thomas Bahmer; Anne-Marie Kirsten; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Marco Gramm; Simone Hummler; Eva Brunnemer; Michael Kreuter; Henrik Watz
Journal:  BMC Pulm Med       Date:  2017-07-25       Impact factor: 3.317

4.  Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Davide Biondini; Elisabetta Balestro; Donato Lacedonia; Stefania Cerri; Rosanna Milaneschi; Fabrizio Luppi; Elisabetta Cocconcelli; Erica Bazzan; Enrico Clini; Maria Pia Foschino Barbaro; Dario Gregori; Manuel G Cosio; Marina Saetta; Paolo Spagnolo
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

5.  Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.

Authors:  Manon Belhassen; Faustine Dalon; Maëva Nolin; Eric Van Ganse
Journal:  Respir Res       Date:  2021-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.